Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. RubinsteinD. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O’Dwyer, A. P. Chen, K. T. Flaherty

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Sort by
Weight
Alphabetically

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

Fingerprint

Medicine & Life Sciences